Breaking News, Collaborations & Alliances

Samsung Bioepis Taps Harrow for U.S. Eye Biosimilar Portfolio

Harrow will assume full responsibility for the commercialization of BYOOVIZ and OPUVIZ in the U.S.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Bioepis Co. Ltd. has entered into a license, development and commercialization agreement (DCA) with Harrow for Samsung Bioepis’ ophthalmology portfolio in the U.S. This includes: BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) OPUVIZ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) The commercial license will become effective upon completion of the transition of commercial rights from Biogen back to Samsung Bioepis, which is expec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters